Ind-Swift Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Navrattan Munjal

İcra Kurulu Başkanı

₹30.3m

Toplam tazminat

CEO maaş yüzdesi	99.9%
CEO görev süresi	29.6yrs
CEO sahipliği	1.6%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Nov 20

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Oct 20

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

Jul 02

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Apr 13

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Jul 22

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Jul 12

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Feb 17

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

Dec 30

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Nov 11

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Jun 27

CEO Tazminat Analizi

Navrattan Munjal'un ücretlendirmesi Ind-Swift Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹4b
Jun 30 2024	n/a	n/a	₹4b
Mar 31 2024	₹30m	₹30m	₹4b
Dec 31 2023	n/a	n/a	₹432m
Sep 30 2023	n/a	n/a	₹513m
Jun 30 2023	n/a	n/a	₹450m
Mar 31 2023	₹36m	₹36m	₹476m
Dec 31 2022	n/a	n/a	₹113m
Sep 30 2022	n/a	n/a	-₹2m
Jun 30 2022	n/a	n/a	-₹11m
Mar 31 2022	₹36m	₹36m	-₹21m
Dec 31 2021	n/a	n/a	₹301m
Sep 30 2021	n/a	n/a	₹256m
Jun 30 2021	n/a	n/a	₹111m
Mar 31 2021	₹33m	₹33m	-₹31m
Dec 31 2020	n/a	n/a	₹277m
Sep 30 2020	n/a	n/a	₹77m
Jun 30 2020	n/a	n/a	-₹111m
Mar 31 2020	₹30m	₹30m	-₹212m
Dec 31 2019	n/a	n/a	-₹734m
Sep 30 2019	n/a	n/a	-₹211m
Jun 30 2019	n/a	n/a	-₹35m
Mar 31 2019	₹18m	₹18m	₹289m
Mar 31 2018	₹18m	₹18m	₹220m

Tazminat ve Piyasa: Navrattan 'nin toplam tazminatı ($USD 358.70K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 42.67K ).

Tazminat ve Kazançlar: Navrattan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Navrattan Munjal (72 yo)

29.6yrs

Görev süresi

₹30,308,000

Tazminat

Mr. Navrattan R. Munjal has been a Managing Director of Ind-swift Laboratories Ltd. since March 29, 2001 and serves as its Chairman. He served as President of Indian Drug Manufacturers’ Association until J...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Navrattan Munjal	Chairman & MD	29.6yrs	₹30.31m	1.56% ₹ 94.6m
Himanshu Jain	Joint MD & Whole Time Director	21.3yrs	₹37.88m	0.69% ₹ 41.8m
Rishav Mehta	Executive Director	14.7yrs	₹15.16m	0.77% ₹ 47.0m
Sahil Munjal	President of Operations & Special Assignments and Executive Director	4.8yrs	₹17.92m	0.011% ₹ 694.9k
Sri Sharma	Non-Executive Independent Director	12.2yrs	₹186.75k	Veri yok
Ashwani Vig	Non-Executive Independent Director	4.8yrs	₹123.75k	Veri yok
Neerja Chathley	Non-Executive Independent Woman Director	5.5yrs	₹85.50k	Veri yok
Rajinder Gupta	Non-Executive Independent Director	3.4yrs	₹148.50k	Veri yok
Param Singh	Independent Director	less than a year	Veri yok	Veri yok

5.5yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INDSWFTLAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Ind-Swift Laboratories Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Financial Officer recently sold ₹4.2m worth of stock

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2024

Ind-Swift Laboratories Limited Appoints Mr. Param Bir Singh as an Independent Director

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

Group Head of Human Resources recently sold ₹3.3m worth of stock

Chief Accounts Officer recently sold ₹1.6m worth of stock

Recent updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Second quarter 2025 earnings released: EPS: ₹0.07 (vs ₹5.36 in 2Q 2024)

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Chief Financial Officer recently sold ₹4.2m worth of stock

Ind-Swift Laboratories Limited to Report Q3, 2025 Results on Feb 14, 2025

Investor sentiment deteriorates as stock falls 21%

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹2.92 in 1Q 2024)

Ind-Swift Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

Investor sentiment improves as stock rises 24%

Ind-Swift Laboratories Limited Appoints Mr. Param Bir Singh as an Independent Director

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

New minor risk - Share price stability

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Full year 2024 earnings released: EPS: ₹71.24 (vs ₹8.06 in FY 2023)

New minor risk - Share price stability

Ind-Swift Laboratories Limited to Report Q4, 2024 Results on May 13, 2024

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 15%

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Essix Biosciences Limited.

Third quarter 2024 earnings released: EPS: ₹3.29 (vs ₹4.65 in 3Q 2023)

Ind-Swift Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Second quarter 2024 earnings released: EPS: ₹5.36 (vs ₹4.29 in 2Q 2023)

Ind-Swift Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: ₹2.92 (vs ₹3.36 in 1Q 2023)

Ind-Swift Laboratories Limited to Report Q1, 2024 Results on Aug 09, 2023

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Group Head of Human Resources recently sold ₹3.3m worth of stock

Investor sentiment improves as stock rises 16%

Chief Accounts Officer recently sold ₹1.6m worth of stock

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: ₹4.65 (vs ₹2.71 in 3Q 2022)

Insider recently sold ₹1.2m worth of stock

Second quarter 2023 earnings released: EPS: ₹4.29 (vs ₹4.14 in 2Q 2022)

Insider recently sold ₹1.6m worth of stock

Ind-Swift Laboratories Limited to Report Fiscal Year 2023 Results on May 30, 2023

First quarter 2023 earnings released: EPS: ₹3.36 (vs ₹3.18 in 1Q 2022)

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2022

Ind-Swift Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: ₹0.36 loss per share (vs ₹0.53 loss in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹4.14 (vs ₹1.68 in 2Q 2021)

Investor sentiment deteriorated over the past week

Soft Air General Trading LLC agreed to acquire Ind-Swift Middle East FZ-LLC from Ind-Swift Laboratories Limited (BSE:532305) for approximately $2 million.

First quarter 2022 earnings released: EPS ₹3.18 (vs ₹0.77 in 1Q 2021)

High number of new directors

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings released: ₹0.53 loss per share (vs ₹4.28 loss in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insider recently sold ₹1.0m worth of stock

Independent Director has left the company

Insider recently sold ₹1.4m worth of stock

Investor sentiment improved over the past week

Insider recently sold ₹2.1m worth of stock

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Third quarter 2021 earnings released: EPS ₹1.95 (vs ₹1.90 loss in 3Q 2020)

Ind-Swift Laboratories Limited to Report Q3, 2021 Results on Feb 12, 2021